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doi:10.1016/j.jfma.2011.07.007Background/Purpose: Lower sympathetic and parasympathetic function increases the
morbidity in Parkinsonian patients. We conducted this retrospective study to elucidate
the effect of subthalamic deep brain stimulation (STN-DBS) on autonomic cardiovascular
regulation of patients with Parkinson’s disease.
Methods: Twelve men and four women with advanced Parkinson’s disease (mean age: 63 years)
who underwent bilateral STN-DBS were followed up for 9e32 months. Daytime electrocardiog-
raphy for 5 minutes and rating scores were recorded before and after surgery. Good response
was defined as improvement >50% in the Unified Parkinson’s Disease Rating Scale (UPDRS), and
a fair response as improvement between 10% and 50% after surgery. Digitalized electrocardi-
ography signals such as high-frequency power [HF; 0.15e0.45 Hz, to reflect vagal (parasympa-
thetic) regulation], low-frequency power (LF; 0.04e0.15 Hz, contributed from mixed
sympathetic and parasympathetic divisions), and the fraction of LF/(HF þ LF) in normalized
units (LF%, to reflect sympathetic regulation) were transformed with fast Fourier transforma-
tion to power spectrum and heart rate variables.
Results: Six male and two female patients were good responders and the others were fair
responders. There were no significant differences in height, weight, duration of disease, le-
vadopa equivalent daily dose, preoperative and postoperative UPDRS, and DBS-off and levo-
dopa-off UPDRS between the good and fair response groups. There were no significant
differences between the good and fair response groups for preoperative heart rate interval,
LF values, LF% values, and HF values. Compared with preoperative values, the good responsetw (T. Harnod).
ight ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
594 S.-Y. Chen et al.group showed a significant increase in LF but not in heart rate, LF%, and HF after surgery.
In contrast, the fair response group showed no significant change in all heart rate variables
postoperatively.
Conclusion: Our study showed an improvement in autonomic cardiovascular regulation in
Parkinsonian patients with >50% improvement in rating scale after STN-DBS, which implied
morbidity reduction in nonmotor symptoms among such patients.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Impaired autonomic cardiovascular regulation, with lower
sympathetic and parasympathetic function, has been
reported in patients with Parkinson’s disease (PD), which is
a nonmotor symptom of PD and increases a long-term
morbidity in patients.1e3 Parkinsonian patients with
impaired autonomic function experience a more rapid
deterioration in functional performance; therefore, treat-
ment of these patients may require earlier levodopa
supplementation or increased dosage.3 In addition to
pharmacological treatment, subthalamic nucleus deep
brain stimulation (STN-DBS) is an effective modality for
treating advanced PD.4 We have previously shown that
patients can achieve significant improvement in the Unified
PD Rating Scale (UPDRS) and reduction in levodopa equiv-
alent daily dose (LEDD) scores after STN-DBS.5
Kaufmann et al have reported increasing heart rate in
Parkinsonian patients after STN-DBS, although sympathetic
or parasympathetic indicators were not examined in a long-
term follow-up study.6 Frequency-domain analysis of heart
rate variability (HRV) is a sophisticated and noninvasive tool
for studying neural regulation of the heart rate. The stan-
dard procedures and interpretation of HRV analysis were
first reported in 1996.7 We have applied a modification of
these procedures to investigate autonomic cardiovascular
regulation in aging and epilepsy patients.8,9 In this retro-
spective study of a cohort of Parkinsonian patients with
bilateral STN-DBS, we used the same technology to inves-
tigate the long-term effect of STN-DBS on autonomic
cardiovascular regulation.
Patients and methods
Patients and controls
We consecutively enrolled 12 male and 4 female patients
with advanced PD (mean age: 63 years, range: 47e79
years), who underwent bilateral STN-DBS and were fol-
lowed up for 9e32 months (mean: 18.88 months) post-
operatively. All patients met the clinical criteria for PD
before surgery, in that at least two of the cardinal symptoms
were present. The core assessment program was used for all
patients, including an acute levodopa test to measure the
effect of levodopa on the UPDRS.10 The following assess-
ments weremade: behavior was videotaped, Hoehn and Yahr
stage was assessed, rapid alternating movements were time
tested, walking was assessed as the time required to walk
a distance of 7 m, a tremorography test was performed,
the Mini-Mental State Examination was administered, andmorphological imaging was acquired with magnetic reso-
nance imaging (MRI).
None of these patients had evidence of arrhythmia,
diabetes mellitus, multiple system atrophy, or pure auto-
nomic failure. Patients who were taking propranolol or
atenolol were excluded from this study because of the
sympatholytic effects of such medications. The Ethical
Committee of the Tzu Chi University and Hospital approved
this study. All of the patients gave their informed consent
at enrollment.
Surgical procedures
We used MRI and microelectrode recording to target the
STN.5 The standard MRI (General Electric, 1.5 T; Milwaukee,
WI, USA) settings were 0.75-mm thickness for T1W axial
images, 2-mm thickness for T2W axial images, and 3-mm
thickness for T2W coronal images. All images were taken
on contiguous slices. The images were transferred into the
Digital Imaging and Communications in Medicine database
and to the BrainLab Vector-Vision (Westchester, IL, USA)
neuronavigation workstation for three-dimensional recon-
struction. The tentative surgical target coordinates for the
tip of the permanent implantable electrode were set at the
lowest central border of the STN by direct visualization on
MR images. On the axial slice, this location was about
1e2 mm lateral of the red nucleus at the level of the
superior colliculus of the midbrain. A Leksell G-frame
(Elekta Instruments, Atlanta, GA, USA) was used for the
stereotactic procedure. The electrodes were implanted
under fluoroscopic guidance after the microelectrode
recording procedures. Stereotactic intraoperative fluoros-
copy was used for the guidance to achieve final electrode
position. The final electrode coordinates were confirmed by
MRI within 3 months postoperatively. The details of the
surgical procedures have been published previously.5
Two weeks after surgery, we started STN-DBS with
a frequency of 130 Hz, pulse width of 60 microseconds and
amplitude of 0.5 V. The amplitude of DBS in each patient
was gradually increased upon the response of the patient’s
motor symptoms, and with maximal amplitude of 4 V.
Outcome assessment of STN-DBS
After surgery, we conducted follow-up visits with the
patients at regular intervals and compared the follow-up
rating scores and LEDD with the preoperative baseline drug-
off measures (without levodopa for at least 12 hours). On
follow-up examinations, UPDRS scores were recorded
during the periods of DBS-on and DBS-off, both under the
condition of drug-off. The effect of STN-DBS was defined as
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was determined by comparing the score of DBS-on, drug-off
to the preoperative drug-off score. Patient outcome was
defined as good response if the improvement rate was >50%
and fair if the improvement rate was between 10% and 50%
after STN-DBS.
Heart rate recording and frequency-domain
analysis of HRV
Many muscle tremors are recorded in a patient during
drug-off periods; daytime electrocardiograms (ECGs) for
5 minutes were recorded in drug-on periods before
surgery and in DBS-on and drug-on periods at follow-up for
comparison. Each awake patient lay in a quiet and
comfortable head-up 45-degree posture during heart rate
recording. Lead I ECG signals were recorded using an analog-
to-digital converter with a sampling rate of 512 Hz.
Frequency-domain analysis was performed using a nonpara-
metric method of fast Fourier transformation. The direct
current component was deleted and a Hamming window was
used to attenuate the leakage effect. For each time
segment (288 seconds; 2048 data points), our algorithm
estimated the power spectrum density on the basis of fast
Fourier transformation. The resultant power spectrum was
corrected for attenuation that resulted from the sampling
and the Hamming window.9 The power spectrum was
subsequently quantified into standard frequency-domain
measurements as defined by the Task Force of the Euro-
pean Society of Cardiology and the North American Society of
Pacing and Electrophysiology. These included the R-R inter-
vals (the intervals between two neighboring R waves, RR),
high-frequency power (HF; 0.15e0.45 Hz), low-frequency
power (LF; 0.04e0.15 Hz), and LF% [LF/(HF þ LF) in
normalized units]. The HF and LF data were logarithmically
transformed to correct for any skew in the distribution. The
LF was contributed from mixed sympathetic and para-
sympathetic divisions. TheHFwas considered to reflect vagal
(parasympathetic) regulation, and the LF%was considered to
mirror sympathetic regulation.7e9
Statistical analysis
Data are presented as mean  standard error. The signifi-
cance of differences between good and fair response
groups was analyzed using Student t test. Paired t tests
were performed for comparisons between preoperative and
postoperative values in the same group of patients. All
statistical assessments were evaluated at the 0.05 level of
significant difference.
Results
Clinical outcome of STN-DBS
At the end of our follow-up study, six male and two female
patients were categorized as good responders (63.13 
2.28% improvement of UPDRS), whereas the other six male
and two female patients were categorized as fair responders
(30.59  3.53% improvement of UPDRS, p < 0.001) (Table 1).There were no significant difference in height, weight,
duration of PD, LEDD, preoperative and postoperative
UPDRS, and DBS-off and drug-off UPDRS between good and
fair response groups (Table 1). Compared with the fair
response group, the good response group had significantly
lower UPRDS scores during the postoperative DBS-on and
drug-off period (33.63  3.55 vs. 47.75  3.01, pZ 0.009).
One female patient in the fair response group who could
not tolerate the discomfort of DBS-off symptoms at the end
of 25 months follow-up refused to undergo assessment of
postoperative LEDD and DBS-off, drug-off UPDRS values.
Heart rate and heart rate variables after STN-DBS
There was no significant difference between fair and good
response groups for preoperative RR, LF, LF%, and HF
values. Figure 1 demonstrates changes in heart rate vari-
ables before and after STN-DBS. Compared with preopera-
tive values, the good response group showed a significant
increase in LF (5.04  0.36 ln[ms2] vs. 3.95  0.39 ln[ms2],
p Z 0.026), but not in RR, LF%, and HF values, after
surgery. In contrast, the fair response group showed no
significant change in heart rate variables postoperatively
compared with preoperative values.
When we analyzed the changes (values after STN-
DBS  values before STN-DBS) in heart rate and variables,
there was no significant difference between fair and good
response groups (RR, p Z 0.17; LF, p Z 0.18; LF%,
p Z 0.88; HF, p Z 0.089).
Discussion
Although STN-DBS has been a promising treatment option
for advanced PD for more than a decade,4,11 it has
remained unclear what long-term neurophysiological
changes in the autonomic nervous system occur. The typical
stimulation paradigm for STN-DBS includes sustained
high-frequency (usually > 100 Hz) and high-voltage
(usually > 1 V) stimulation. Some studies have found that
the tetanic stimulation silences subthalamic neurons during
this treatment.12,13 An anatomical study has revealed the
connections between the subthalamic nucleus and hypo-
thalamus,14 which is known as an autonomic regulatory
region. Although the STNehypothalamus connection has
been documented, the detailed communication and inter-
action between these two deep brain structures are not
yet clear. Combining these with our results, long-term
stimulation might silences the subthalamus and interacts
with central autonomic regulatory regions to cause
a significant increase in HRV among patients with prominent
or good response to STN-DBS. It implies that STN-DBS has
a morbidity reduction effect on autonomic cardiovascular
regulation, which is a nonmotor symptom in these patients.
In this study, we observed 16 Parkinsonian patients with
STN-DBS for a mean duration of 18.88 months. There was no
long-term change in heart rate or RR interval at the end of
follow-up study for either fair or good response patients
when compared with a previous short-term report of
increasing heart rate with STN-DBS.6 This reveals that
cardiovascular regulation may be more prominently influ-
enced by STN-DBS in the short-term, whereas the long-term
Table 1 Clinical features of our patients with subthalamic deep brain stimulation
Sex/
Age (y)
Height
(cm)
Weight
(kg)
Duration
of PD (y)
LEDD
pre-op
LEDD
post-op
UPDRS total score Follow-up
(mo)Pre-op
Drug-off
Pre-op
Drug-on
Post-op
DBS-on
Drug-off
Post-op
DBS-off
Drug-off
Improvement
by STN-DBS
(%)
Fair response
M/71 171 106 5 610 375 61 54 48 76 21.31 32
F/65 148 65 10 1385 e 99 51 61 e 38.38 25
M/70 160 60 7 567.5 125 73 55 42 81 42.47 24
M51 163 65 14 577.5 360 93 39 57 133 38.71 24
M/79 170 65 6 882.5 385 64 57 53 63 17.19 9
M/75 171 72 8 567.5 187.5 58 47 38 61 34.48 13
F/54 154 64 8 1309.38 940 48 23 39 79 18.75 12
M/75 164 60 11 1385 500 66 48 44 68 33.33 12
162.63 
2.96
69.63 
5.36
8.63 
1.03
910.55 
136.71
410.36 
100.49
70.25 
6.18
46.75 
3.94
47.75 
3.01
80.14 
9.29
30.59 
3.53
18.88  3
Good response
M/52 162 71 5 750 332.5 101 34 33 87 67.33 13
M/53 174 79 10 1788.8 187.5 157 72 41 100 73.89 12
F/62 154 47 12 567.5 700 75 75 25 43 66.67 24
M/65 155 58 10 1130 288.75 96 25 44 100 54.17 24
F/56 155 52 5 1038.8 250 50 18 18 62 64 29
M/47 174 59 6 625 500 88 26 38 93 56.82 12
M/75 153 63 9 562.5 375 108 87 45 76 58.33 24
M/58 166 63 10 832.5 457.5 69 45 25 80 63.77 13
161.63 
3.12
61.5 
3.59
8.38 
0.94
911.89 
145.66
386.41 
57.79
93 
11.31
47.75 
9.4
33.63 
3.55*
80.13 
6.98
63.13 
2.28*
18.88 
2.48
Data are presented as mean  SE. Improvement by STN-DBS Z [UPRDS (Pre-op, Drug-off)  UPDRS (Post-op, DBS-on, Drug-off)]/UPRDS (Pre-op, Drug-off) in normalized units.
*A p value <0.05, Student t test, good response group versus fair response group.
FZ female; LEDDZ levodopa equivalent daily dose; MZmale; PDZ Parkinson’s disease; Post-opZ postoperative; Pre-opZ preoperative; SEZ standard error; STN-DBSZ subthalamic
deep brain stimulation; UPDRS Z Unified Parkinson’s Disease Rating Scale.
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Figure 1. Changes of RR, LF, LF% [LF/(HF þ LF) in normalized units], and HF after subthalamic deep brain stimulation relative to
preoperative values. Data are presented as mean  standard error. *A p value <0.05, paired t test. The good response group
showed significant increase in LF (p Z 0.026) but not in RR, LF%, and HF. The fair response group showed no significant change in
heart rate variables. HFZ high-frequency power; LF Z low-frequency power; Post-op Z postoperative; Pre-op Z preoperative.
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gation to identify.
STN-DBS has been well documented to improve patients’
daily performance in many studies, as measured by the
rating scores of PD.4,5,11 From these studies, the average
improvement rates of UPDRS were usually 40e50% after
STN-DBS. Based on previous reports, we defined the good
response rate to be >50% in the present study. However, to
date, there is no universal standard to define good, fair, or
poor improvement after STN-DBS in Parkinsonian patients.
A previous study revealed no change in heart rate
variables in 14 Parkinsonian patients with STN-DBS duringa 12-month follow-up.15 Gentil et al have reported signifi-
cant improvement in respiratory function after STN-DBS.16
Their results have suggested that autonomic function of
visceral organs is increased by STN-DBS, which inspired us
to analyze our data from a different viewpoint than in
previous studies. In our preliminary analysis of follow-up
data, we also found no significant difference in heart rate
variables when we analyzed pooled data of all patients.
However, if we separated the patients into good and fair
responders to STN-DBS, we found a significant increase in
LF among the good responders. Although we did not find
significant changes in the sympathetic indicator, LF%, and
598 S.-Y. Chen et al.the parasympathetic indicator, HF, probably because of
a limited number of follow-up patients. We believe that the
analysis in a larger group of patients in the future could
help to elucidate the details of the effects of STN-DBS on
autonomic function.
Autonomic cardiovascular dysregulation in PD has been
documented in central and peripheral autonomic regula-
tory regions.3,17,18 In addition to the hypothalamus, the
insular cortex,17 the dorsal motor nucleus of the vagus,18
the intermediolateral nucleus of the thoracic cord,
sympathetic ganglia, and the sacral parasympathetic nuclei
have been found to be affected by PD.3,18 Either sympa-
thetic or parasympathetic division could be affected by PD,
and these two divisions can be individually studied by
frequency-domain analysis of HRV. However, the change in
autonomic cardiovascular regulation may come from the
effects of different dosages of anti-Parkinsonian medica-
tions. In previous studies, levodopa could induce negative
effects on autonomic function by decreasing central
sympathetic outflow, which was caused by the central D2
agonist action.19 The selective inhibitor of monoamine
oxidase, selegiline, can diminish sympathetic activity.20 In
contrast, the catechol-O-methyltransferase inhibitor tol-
capone does not influence autonomic cardiovascular regu-
lation after 6 months of treatment.21 In patients with
advanced PD, treatment with a combination of anti-
Parkinsonian medications is usually given, and it would be
a confounding factor for studying autonomic function of
patients. In this study, we observed that the good response
group had a reduction of LEDD from 911.89  145.66 to
386.41  57.79 and the fair response group had a reduction
from 910.55  136.71 to 410.36  100.49 postoperatively.
Because there was no significant difference in LEDD
between the two groups pre- and postoperatively, the
observed change in heart rate variables was considered to
be caused by STN-DBS alone.
HRV could physiologically vary widely, even in healthy
individuals,7 possibly due to the effects of circadian
rhythms,22 sex,9 age,9 weight,23 or body mass index.24 In
the present study, all heart rate variables were recorded
and analyzed during daytime to avoid major circadian
effects. Obtaining recordings and heart rate variables
before and after STN-DBS in the same patients with the
same posture can minimize interindividual anthropometric
and posture-confounding effects. We planned to study the
effects of STN-DBS on HRV over time; therefore, changes in
body weight or body mass index in any patient could not be
avoided. However, we believe that our study may be
accurate with regard to showing the long-term effects of
STN-DBS on HRV.
HRV can be studied using 5-minute,8,9,25 10-minute,26 or
24-hour ECG recording with heart rate measured by
frequency-domain analysis of HRV in a single patient. A
24-hour ECG recording can provide circadian changes in
HRV and is considered to be the standard procedure.
However, a 5- or 10-minute ECG recording is highly assess-
able and correlated with a 24-hour recording, and a positive
result suggests a 24-hour recording of ECG with analysis of
circadian changes of HRV in patients.25,26
In STN-DBS treated Parkinsonian patients, we found
significantly increased LF of HRV in patients with >50%
improvement in UDPRS scores. These findings suggest anassociation of improvement in autonomic cardiovascular
regulation and good response to STN-DBS, which imply
probable morbidity reduction in nonmotor symptoms among
such patients with STN-DBS.Acknowledgment
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